Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep995 | Thyroid | ECE2020

Performance of a dual-component molecular assay in cytologically indeterminate thyroid nodules

Sponziello Marialuisa , Verrienti Antonella , Pecce Valeria , Abballe Luana , Grani Giorgio , Ramundo Valeria , Fadda Guido , Brunelli Chiara , Durante Cosimo , Filetti Sebastiano

Background: Deciding whether patients with a cytologically indeterminate thyroid nodule should be referred for surgery or for active surveillance is an important challenge for clinicians. The aim of this study was to evaluate the performance of a novel dual-component molecular assay as an ancillary molecular method for resolving indeterminate thyroid nodule cytology.Methods: We selected 156 thyroid nodules from those that had undergone both FNA cytology ...

ea0073oc5.5 | Oral Communications 5: Thyroid | ECE2021

Role of miR-139–5p in radioiodine-refractory thyroid cancers

Pecce Valeria , Abballe Luana , Sponziello Marialuisa , Brunelli Chiara , Verrienti Antonella , Annunziata Salvatore , Grani Giorgio , Fadda Guido , Salvatori Massimo , Russo Diego , Durante Cosimo

Radioiodide 131I (RAI) is the therapy of choice for radioiodine-avid differentiated thyroid cancer (DTC). However, 5–15% of DTC patients become RAI refractory (RAIR), and the 10-year survival rate for metastatic disease decreases to 10%. The failure of RAI response is mainly due to the loss of thyroid differentiation, that leads to the loss of expression/function of components of iodide metabolism, first of all the Na/I symporter (NIS). The finding that the MAPK pathway i...